Status:

RECRUITING

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Lead Sponsor:

Oxford Biodynamics Inc.

Collaborating Sponsors:

Community Clinical Oncology Research Network, LLC

Conditions:

Cancer

Immunotherapy

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibito...

Detailed Description

The Episwitch CiRT® (Checkpoint inhibitor Response Test) predicts how a patient will respond to immune checkpoint inhibitor (ICI) therapies by delivering a binary response likelihood profile (High Pro...

Eligibility Criteria

Inclusion Criteria:

  1. 18 years of age or older
  2. Stage III or IV cancer
  3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
  4. ECOG performance status ≤ 2
  5. Clinically eligible for ICI therapy
  6. Able to read, understand and provide written informed consent.
  7. Willing and able to comply with the study requirements

Exclusion Criteria:

  1. Pregnant or breastfeeding
  2. History of bone marrow or organ transplant
  3. Contra indication for receiving Immune Check Point inhibitor.

Key Trial Info

Start Date :

May 14 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 14 2027

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT06635954

Start Date

May 14 2024

End Date

May 14 2027

Last Update

March 17 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Eastern Connecticut Hematology and Oncology

Norwich, Connecticut, United States, 06360

2

Cancer Center of Middle Georgia

Dublin, Georgia, United States, 31021

3

Carolina Blood and Cancer Care Associates

Rock Hill, South Carolina, United States, 29732

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. | DecenTrialz